Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;30(7):1060-4.
doi: 10.1038/aps.2009.73. Epub 2009 Jun 8.

Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs

Yue Yuan  1 , Xiao-Yan Chen, San-Ming Li, Xiu-Yan Wei, Hui-Min Yao, Da-Fang Zhong
Affiliations

Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs

Yue Yuan et al. Acta Pharmacol Sin. 2009 Jul.

Abstract

Aim: The potential for topical delivery of meloxicam was investigated by examining its pharmacokinetic profiles in plasma and synovial fluid following oral and transdermal administration in Beagle dogs.

Methods: The experiment was a two-period, crossover design using 6 Beagle dogs. Meloxicam tablets were administered orally at a dose of 0.31 mg/kg, and meloxicam gel was administered transdermally at a dose of 1.25 mg/kg. Drug concentrations in plasma and synovial fluid were determined by liquid chromatography-tandem mass spectrometry (LC/MS/MS). The pharmacokinetic parameters were calculated using the Topfit 2.0 program.

Results: The pharmacokinetic results showed that AUC(0-t) (23.9+/-8.26 microg.h.mL(-1)) in plasma after oral administration was significantly higher than after transdermal delivery (1.00+/-0.43 microg.h.mL(-1)). In contrast, the ratio of the average concentration in synovial fluid to that in plasma following transdermal administration was higher than that for an oral delivery. The synovial fluid concentration in the treated leg was much higher than that in the untreated leg, whereas the synovial fluid concentration in the untreated leg was similar to the plasma concentration.

Conclusion: The high concentration ratio of synovial fluid to plasma indicates direct penetration of meloxicam following topical administration to the target tissue. This finding is further supported by the differences observed in meloxicam concentrations in synovial fluid in the treated and untreated joints at the same time point. Our results suggest that transdermal delivery of meloxicam is a promising method for decreasing its adverse systemic effects.Acta Pharmacologica Sinica (2009) 30: 1060-1064; doi: 10.1038/aps.2009.73; published online 8 June 2009.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean concentration-time profiles of meloxicam in synovial fluid and plasma after an oral administration to Beagle dogs at 0.31 mg/kg (n=6).
Figure 2
Figure 2
Mean concentration-time profiles of meloxicam in synovial fluid of the treated leg and in plasma after a transdermal administration to Beagle dogs at 1.25 mg/kg (n=6).
Figure 3
Figure 3
The concentration ratios of synovial fluid to plasma after oral and transdermal administrations for the treated leg to Beagle dogs (n=6).
See this image and copyright information in PMC

References

    1. Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam. Clin Pharmacokinet. 1999;36:115–26. - PubMed
    1. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004;117:100–17. - PubMed
    1. Noble S, Balfour JA. Meloxicam. Drugs. 1996;51:424–30. - PubMed
    1. Gupta SK, Bansal P, Bhardwaj RK, Jaiswal J, Velpandian T. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. Skin Pharmacol Appl Skin Physiol. 2002;15:105–11. - PubMed
    1. Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol. 1996;35:56–60. - PubMed